Highest-materiality recent filing
SS Innovations enters $50M ATM equity offering with Virtu Americas
Entered ATM Sales Agreement with Virtu Americas LLC to sell up to $50M of common stock.
SS Innovations completes world's longest robotic telesurgery over 12,500 miles using SSi Mantra
World record: 12,500-mile (20,000 km) telesurgery from Guyana to India using SSi Mantra, performed by CEO Dr. Sudhir Srivastava.
Milan Rao will step down as Global Chief Operating Officer and Chief Financial Officer on May 25, 2026.
SS Innovations Q1 revenue $11.1M (+117% YoY); net loss narrows to $3.6M; installations up 73%
Revenue $11.1M, up 116.8% YoY from $5.1M; gross margin 48.0% vs 21.2% in Q1 2025.
SS Innovations completes 4,500+ mile telesurgery using SSi Mantra system
Successful remote robotic gastrojejunostomy performed May 2, 2026, from Perth, Australia to Indore, India.
SSi Mantra approved in Colombia, Oman, Sri Lanka, Kenya; total approvals now 11 countries
Regulatory approvals from INVIMA (Colombia, Nov 2025), DGPA&DC (Oman, Nov 2025), NMRA (Sri Lanka, Jan 2026), and PPB (Kenya, Jan 2026).
SSi Mantra surgical robot receives regulatory approval for telesurgeries in Indonesia and the Philippines.
SS Innovations Q4 revenue up 79% to $14.5M; raises $18.6M in private placement
Q4 2025 revenue $14.5M (+79% YoY); gross margin 43.9%; net loss $2.5M ($0.01/share).
SS Innovations completes $18.6M private placement; funds expansion, FDA review mid-2026
Raised $18.6M gross via private placement of 5,774,839 shares at $3.00-$4.01 per share.
SS Innovations: preliminary Q4 revenue $15.0M, FY revenue $43.0M, installations up 119%
Q4 2025 revenue expected ~$15.0M, up 85% YoY; Q4 Mantra installations 37, up 68% YoY.
SS Innovations appoints Milan Rao as CFO and Global COO; CFO Amar resigns
CFO Naveen Kumar Amar resigned Jan 2 for personal reasons; succeeded by Milan Rao as CFO and new Global COO, effective Jan 16.
Submitted 510(k) premarket notification to FDA on Dec 5, 2025 for SSi Mantra system covering general, urological, colorectal, gynecological, and cardiac surgeries.
SS Innovations Q3 revenue $12.8M (+192.5% YoY); net loss narrows to $3.7M
Revenue $12.8M vs $4.4M YoY; gross profit $6.2M (+166.0%) on 48.1% margin.
SS Innovations completes human factors validation study for SSi Mantra; plans FDA 510(k) in Q4 2025
Completed human factors validation study for SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025.
SS Innovations completes world's first pediatric pyeloplasty telesurgery with SSi Mantra
Dr. Chandra Mohan Vaddi performed remote robotic pyeloplasty from ~1,000 miles on a 16-month-old in Hyderabad.
SS Innovations Q2 revenue up 122% to $10M; net loss narrows to $0.3M
Revenue of $10.0M, up 121.8% YoY; gross margin expanded to 59.1% from 31.9%.
SS Innovations announces CFO change; interim CFO steps down, CEO Asia-Pacific named interim CFO
Arvind Palaniappan stepped down as Interim CFO effective July 23, 2025.
SS Innovations completes world's first intercontinental robotic cardiac telesurgery over 4,000 miles
CEO Dr. Sudhir Srivastava performed an atrial septal defect closure remotely from Strasbourg, France to Indore, India on July 19, 2025 using the SSi Mantra 3 system.
SS Innovations surpasses 100 installations of SSi Mantra; >5,000 procedures completed
Over 100 SSi Mantra systems installed in India and six other countries.
World's first robotic telesurgery for weight loss completed with SSi Mantra 3
Two One-Anastomosis Gastric Bypass (OAGB) procedures performed via telesurgery over 560 miles with zero perceptible lag.
SSi Mantra system used in >4,000 surgeries across >100 types with no complications, injuries, or mortalities.
SS Innovations Q1 revenue $5.1M (+40.8% YoY); net loss narrows; FDA submission planned by July 2025
Revenue $5.1M (+40.8% YoY); gross margin 21.23% (up 121 bps); net loss $5.7M ($0.03 diluted) vs $9.8M ($0.06) in Q1 2024.
SS Innovations plans FDA De Novo submission for SSi Mantra 3 in July 2025
Planned De Novo Classification Request to FDA in July 2025 for multispecialty indications including urology, gynecology, general surgery, thoracic and cardiac.
SS Innovations reiterates Q1 revenue guidance of ~$6.4M; April orders up 200% YoY to 9 systems
Q1 2025 revenue expected ~$6.4M with gross margin ~45% (preliminary unaudited).
SS Innovations approved for Nasdaq listing; trading begins April 25 under SSII
Common stock approved for listing on Nasdaq Capital Market; trading begins April 25, 2025 under symbol SSII.
SS Innovations reports ~$22M preliminary 2024 revenue, almost 4x YoY; Q1 2025 est $6.4M
Preliminary 2024 revenue ~$22M (unaudited), up from ~$5.5M in 2023; gross margin improved to 36.9% from 12.3%.
SS Innovations performs India's first 2,000-km North-to-South robotic cardiac telesurgery
SSi Mantra 3 system enabled telesurgery from Gurugram to Bengaluru, covering >2,000 km.
CEO provides $17M in convertible note financing to SS Innovations
Dr. Sudhir Srivastava provided $2M (Dec 2024), $5M (Jan 3, 2025), and $10M (Jan 20, 2025) in convertible notes.
SS Innovations performs world's first robotic cardiac telesurgeries with SSi Mantra 3
Two telesurgeries completed from Gurugram to Jaipur (286 km): IMA harvesting (58 min) and beating-heart TECAB.
BDO India completed re-audit of FY2022 and FY2023; restated financials filed in Form 10-K/A on Dec 6, 2024.
SS Innovations receives CDSCO approval for Telesurgery, Teleproctoring via SSi Mantra
First and only company in India to get CDSCO regulatory approval for telesurgery and teleproctoring capabilities of its SSi Mantra surgical robotic system.
On May 18, 2026, Milan Rao informed the Company that he would step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.
On May 21, 2025, our board of directors appointed Dr. Vishwajyoti P. Srivastava, M.D., who has served as our President and Chief Operating Officer – Asia, to the new position of Chief Executive Officer – Asia Pacific.
Anup Sethi stepped down as the Company’s Chief Financial Officer effective April 30, 2025
Arvind Palaniappan joined the Company as its Interim Chief Financial Officer, effective May 1, 2025
Effective August 20, 2024, SSi expanded its board of directors from five (5) to seven (7) members and Dr. Frederic Moll and Timothy P. Adams were appointed as directors to fill the newly created vacancies on the board.
Effective August 20, 2024, SSi expanded its board of directors from five (5) to seven (7) members and Dr. Frederic Moll and Timothy P. Adams were appointed as directors to fill the newly created vacancies on the board. In addition, Dr. Moll was appointed as non-executive Vice Chairman of the Board of Directors.
Effective July 30, 2023, SSII expanded its board of directors to five (5) members and Dr. Mylswamy Annadurai and Prof. Dr. Somashekhar S.P. were appointed directors to fill the newly created vacancies on the board.
Effective July 30, 2023, SSII expanded its board of directors to five (5) members and Dr. Mylswamy Annadurai and Prof. Dr. Somashekhar S.P. were appointed directors to fill the newly created vacancies on the board.
Max materiality 0.85 · Median 0.60 · Most common event other_material